Design Therapeutics (DSGN) Retained Earnings (2020 - 2026)
Design Therapeutics recorded quarterly Retained Earnings of -$314.6 million in Q1 2026, down 78164.52% quarter-over-quarter from $403000.0 in Q4 2025, and down 28.45% year-over-year from -$439.7 million in Q1 2025.
Design Therapeutics' Retained Earnings history runs 7 years deep, the most recent figure standing at -$314.6 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 28.45% year-over-year to -$314.6 million; the TTM figure through Mar 2026 stood at -$314.6 million (down 28.45% YoY), while the FY2025 annual figure was $403000.0, up 100.18% from the prior year.
- Retained Earnings came in at -$314.6 million for Q1 2026 at Design Therapeutics, down from $403000.0 in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $403000.0 in Q4 2025 to a low of -$314.6 million in Q1 2026.
- A 5-year average of -$127.2 million and a median of -$150.0 million in 2023 frame the typical range for Retained Earnings.
- Across the five-year window, Retained Earnings sank 630900.0% in 2022 and jumped 100.18% in 2025, its largest moves.
- Design Therapeutics' Retained Earnings stood at -$110.8 million in 2022, then jumped by 100.06% to $62000.0 in 2023, then tumbled by 366574.19% to -$227.2 million in 2024, then surged by 100.18% to $403000.0 in 2025, then tumbled by 78164.52% to -$314.6 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$314.6 million, $403000.0, and $358000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Design Therapeutics | 640.15 Mn | 417.32 Mn | - | -314.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -314.60 Mn |
| Dec 31, 2025 | 403,000.00 |
| Sep 30, 2025 | 358,000.00 |
| Jun 30, 2025 | -264.01 Mn |
| Mar 31, 2025 | -244.93 Mn |
| Dec 31, 2024 | -227.21 Mn |
| Sep 30, 2024 | -213.60 Mn |
| Jun 30, 2024 | -200.52 Mn |
| Mar 31, 2024 | -188.73 Mn |
| Dec 31, 2023 | 62,000.00 |
| Sep 30, 2023 | -165.80 Mn |
| Jun 30, 2023 | -150.00 Mn |
| Mar 31, 2023 | -1.98 Mn |
| Dec 31, 2022 | -110.76 Mn |
| Sep 30, 2022 | -3.86 Mn |
| Jun 30, 2022 | -75.72 Mn |
| Mar 31, 2022 | -1.32 Mn |
| Dec 31, 2021 | -244,000.00 |
| Sep 30, 2021 | -4,000.00 |
| Jun 30, 2021 | -12,000.00 |
| Mar 31, 2021 | 2,000.00 |
| Dec 31, 2020 | 156,000.00 |